Addex Therapeutics Ltd
APE1
Company Profile
Business description
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
Contact
Chemin des Mines 9
Geneva1202
CHET: +41 228841555
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,152.30 | 268.20 | -2.85% |
| CAC 40 | 8,103.84 | 290.48 | -3.46% |
| DAX 40 | 23,790.65 | 847.35 | -3.44% |
| Dow JONES (US) | 48,501.27 | 403.51 | -0.83% |
| FTSE 100 | 10,473.41 | 306.70 | -2.85% |
| HKSE | 25,768.08 | 612.94 | -2.32% |
| NASDAQ | 22,516.69 | 232.17 | -1.02% |
| Nikkei 225 | 56,279.05 | 2,474.34 | -4.21% |
| NZX 50 Index | 13,559.63 | 111.08 | -0.81% |
| S&P 500 | 6,816.63 | 64.99 | -0.94% |
| S&P/ASX 200 | 8,935.40 | 246.30 | -2.68% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |